Price Alert

TETRA Technologies Inc. (TTI)

NYSE: TTI · Real-Time Price · USD

5.68

0.09 (1.70%)

At close: Sep 24, 2025, 3:59 PM

5.60

-1.50%

After-hours: Sep 24, 2025, 07:55 PM EDT

1.70% (1D)

Bid	5.6
Market Cap	757.7M
Revenue (ttm)	607.22M
Net Income (ttm)	115.08M
EPS (ttm)	0.92
PE Ratio (ttm)	6.18
Forward PE	18.76
Analyst	Strong Buy
Dividends	n/a

Ask	5.81
Volume	1,337,349
Avg. Volume (20D)	1,614,826
Open	5.67
Previous Close	5.58
Day's Range	5.63 - 5.82
52-Week Range	2.03 - 5.86
Beta	1.40
Ex-Dividend Date	n/a

About TTI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TTI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TTI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

TETRA Technologies Inc. is scheduled to release its earnings on Oct 28, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+18.93%

Shares of energy stocks are trading higher amid a ... Unlock content with Pro Subscription

4 months ago

+3.26%

TTI stock has given up its prior gain. Tetra Technologies shares were trading higher following a Q1 adjusted EPS beat.

News

1 month ago · benzinga.com

Top 2 Energy Stocks That May Fall Off A Cliff This Quarter

As of Aug. 1, 2025, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

1 month ago · seekingalpha.com

TETRA Technologies, Inc. (TTI) Q2 2025 Earnings Call Transcript

TETRA Technologies, Inc. (NYSE:TTI ) Q2 2025 Earnings Conference Call July 30, 2025 10:30 AM ET Company Participants Brady M. Murphy - President, CEO & Director Elijio V.

1 month ago · zacks.com

Tetra Technologies (TTI) Q2 Earnings Match Estimates

Tetra Technologies (TTI) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago.

3 months ago · newsfilecorp.com

Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU

San Diego, California--(Newsfile Corp. - June 25, 2025) - Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based t...